With the confirmation that Iclepertin has no effects, the long-term extension study (CONNEX-X) will also be discontinued. However, Iclepertin appears to have no significant issues regarding safety.

Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.

the long-term extension study of iclepertin (CONNEX-X; ClinicalTrials.gov Identifier: NCT05211947) has been discontinued. “While these findings are disappointing, we remain dedicated to finding ...

4–6 Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. 13 Boehringer Ingelheim is a biopharmaceutical company active in both human and ...

4-6 Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. 13 Boehringer Ingelheim is a biopharmaceutical company active in both human and ...

4–6 Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately.13 Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in ...

CONNEX was the largest program for cognitive impairment in schizophrenia to date. Boehringer believes that the results will aid scientific understanding and inform future research for patients ...

Our gratitude goes to the patients and clinical investigators whose time and commitment made this research possible.” CONNEX was the largest program for cognitive impairment in schizophrenia to date.